BONITA SPRINGS, Fla., Sept. 28 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, is pleased to announce the appointment of Mr. Neil Flanzraich as Executive Chairman of the Board of Directors.
"The appointment of Mr. Flanzraich is a very important milestone for Tigris Pharmaceuticals' future," said Edmundo Muniz, MD, PhD, President and CEO of Tigris, adding, "Neil brings to Tigris extraordinary ability and pharmaceutical industry experience and a remarkable track record of success. We are extremely pleased to welcome him to our company."
Mr. Flanzraich also serves as Chairman of ParinGenix, Inc., another privately owned biotechnology company. He is also the founder and a principal of a venture capital firm, Leviathan Biopharma Group, LLC.
For over seven years, prior to its sale in 2006, Mr. Flanzraich served as Vice Chairman and President of IVAX Corporation, an international pharmaceutical company acquired by TEVA Pharmaceutical Industries, Ltd. Prior to his tenure at IVAX, Mr. Flanzraich served as Chairman of the Life Sciences Legal Practice Group of Heller Ehrman LLP, a law firm, and for thirteen years, he worked at Syntex Corporation, an international pharmaceutical company, where he was Senior Vice President and member of the Corporate Operating Committee.
"I am delighted to become Tigris Pharmaceuticals' Executive Chairman," said Mr. Flanzraich. "I am joining a leadership team with deep expertise and an impressive record of accomplishment. Our combined capabilities, shared values and focus and the company's exciting pipeline will make Tigris an extraordinarily successful enterprise."
Mr. Flanzraich serves as a director of Equity One, Inc., a real estate company, Continucare Corporation, a mixed model provider of primary care physician services, Chipotle Mexican Grill, a developer and operator of fast-casual, fresh Mexican food restaurants in the United State
|SOURCE Tigris Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved